Walk into almost any clinical research organization right now and you will find the same scene. There is an AI initiative. There is a data science team. There is a proof of concept that demoed beautifully in a room full of executives. And there is a quiet, unresolved question underneath all of it: can the data actually feed this thing in production, reliably, across every study, without someone hand-stitching it together each time.
That question, not the choice of model, is where most programs stall. The interesting shift in 2026 is that the industry has started to say so out loud. Across contract research organizations, the argument has quietly moved from "which AI capability should we buy" to "is our data operations layer ready to carry it." That is the right question. It is also the harder one.
What "data operations" actually means in a trial
Data operations is the layer between raw collection and anything useful. It is the ingestion, standardization, reconciliation, lineage, validation, and delivery of trial data into a form that a query, a report, a submission, or a model can trust. In a modern study that data arrives from electronic data capture, labs, wearables and sensors, imaging, patient-reported outcomes, and a growing list of third-party sources, each with its own format and its own idea of what a patient record looks like.
The job of the data operations layer is to make all of that reconcilable and reproducible. Not once, for one study, in one heroic sprint. Every time, across studies of different sizes and sponsors, with an audit trail that holds up under scrutiny. When people say a trial was "data limited," this layer is usually what they mean, even if they name the model or the team instead.
The model is almost never the bottleneck
The failure pattern in AI is now well documented, and it is not about algorithms. Gartner predicts that through 2026, organizations will abandon 60% of AI projects that are not supported by AI-ready data, and in a 2024 survey it found that 63% of organizations either lack the right data management practices for AI or are unsure whether they have them. Separately, Gartner expected at least 30% of generative AI projects to be abandoned after proof of concept by the end of 2025, citing poor data quality, weak risk controls, rising cost, and unclear business value as the drivers.
MIT's 2025 research on enterprise AI pointed in the same direction: the large majority of generative AI deployments produced no measurable financial return, and the small group that did tended to have fixed their data foundation and workflow integration first. The through-line is consistent. The bottleneck sits upstream of the model, in the data layer that was built for periodic reporting and is now being asked to feed systems that consume data continuously.
Why 2026 is different: more data, and AI everywhere in the workflow
Two forces are colliding. The first is raw volume. Tufts Center for the Study of Drug Development reports that a Phase III protocol now generates roughly 5.9 million data points on average, growing at about 11% a year since 2020. A decade ago that figure was closer to 3.6 million, itself about three times the volume of the prior decade. The curve is not flattening. More endpoints, more biomarker and genetic data, more sources per study.
The second force is that AI is no longer a side project. It is being pushed into authoring, into outcome assessment, into monitoring, into the everyday work of clinical operations. When AI moves from a pilot into the production workflow, the standard it demands of the data changes. Analytics-ready data was good enough for a monthly report. AI-ready data has to be governed at the level of the individual asset, carry live metadata, hold its lineage, and pass quality gates at the cadence the model runs, not the cadence a reporting team publishes. That is a materially higher bar, and most environments were not built to clear it.
What a working data operations layer looks like
The organizations that get this right tend to share the same building blocks. Ingestion is automated and source-agnostic, so a new instrument or partner feed is an onboarding task rather than a rebuild. Standardization is enforced once, centrally, against common clinical data models rather than re-negotiated per study. Lineage is captured automatically, so any figure can be traced back to its source without a forensic exercise. Validation runs as a gate in the pipeline, not as a manual pass at the end. And the whole thing is reproducible across labs and studies, which is what lets a result survive being checked by someone who was not in the room when it was produced.
None of this is glamorous. It is plumbing. But it is the plumbing that decides whether an AI capability is a demo or a dependable part of the operation. Skip it and every model becomes a one-off, rebuilt by whoever happens to be on the team that quarter.
Why this hits clinical research harder than most industries
A retailer with messy data ships a slightly worse recommendation. A clinical research organization with messy data has a harder problem, because the environment is regulated and the data has to be defensible. It is not enough for a pipeline to produce the right answer. It has to be able to show its work: where each value came from, what transformed it, who validated it, and whether that chain would hold up in front of a reviewer.
That is what makes the AI governance seam so sharp in this sector. Many organizations are now running two layers at once, an enterprise automation layer built by central engineering and a citizen-developer layer built by domain teams close to the science. Both are valuable. The friction lives in the gap between them, in whether the governed pipeline and the fast local tool agree on what the data means and can both be trusted in a validated context. Closing that seam is a data operations problem before it is an AI problem.
Signs your data operations layer is not ready
A few symptoms show up again and again. Data preparation eats the team. Industry surveys have long put data preparation at roughly 45% of a data professional's time, more than model training, selection, and deployment combined, and in clinical settings that number climbs when reconciliation is manual. Every new study feels like starting over rather than configuring a known process. Nobody can quickly answer where a specific number came from. A meaningful share of collected data never supports a primary or key secondary endpoint, which Tufts and TransCelerate put at nearly one third of procedures and associated data, yet it still has to be managed, stored, and cleaned. And the database build for a complex trial stretches out, with high-complexity studies taking roughly 19 weeks to design a database, about 36% longer than low-complexity ones. If several of these are true at once, the constraint is the data layer, whatever the roadmap says.
Where the business case shows up
The payoff of fixing this layer is not abstract. In one engagement, building a domain-specific AI query agent on top of a properly curated data foundation, a life sciences data team saw queries run 35% faster, with more than 250 curated fields and a tenfold increase in the data coverage available to the people asking questions. The model mattered, but the model only worked because the data beneath it was governed and reconcilable first.
The same principle shows up in data harmonization work. Unifying more than 50 national datasets into a single analytics platform, used by over 1,000 people across more than 15 countries, cut manual preparation by about 60%. The headline was the platform. The value was the operations layer underneath that made the platform trustworthy at scale. In both cases the lesson is the same one the failure statistics keep repeating: invest in the layer that feeds the model, and the model starts to earn its keep.
Where the sales angle naturally fits
If your team is staring at a stalled AI pilot, or bracing for the data volume of the next protocol, the most useful next move is usually not another model evaluation. It is an honest look at the data operations layer: how data gets in, how it gets standardized, how it gets validated, and whether any of that is reproducible without heroics. That is the work DataDrill does, embedded alongside data and clinical teams in regulated environments, building the pipelines and governance that let AI run in production rather than in a demo.
Final Thought
The winners in clinical AI will not be the teams with the cleverest model. They will be the teams whose data was ready when the model arrived.